Triple-negative breast cancer

William D Foulkes; Ian E Smith; Jorge S Reis-Filho

doi:10.1056/NEJMra1001389

Triple-negative breast cancer

N Engl J Med. 2010 Nov 11;363(20):1938-48. doi: 10.1056/NEJMra1001389.

Authors

William D Foulkes¹, Ian E Smith, Jorge S Reis-Filho

Affiliation

¹ Departmentof Oncology and Human Genetics, Research Institute of the McGill University Health Centre, and the Lady Davis Institute of the Jewish General Hospital, McGill University, Montreal, QC H2W 1S6, Canada. william.foulkes@mcgill.ca

PMID: 21067385
DOI: 10.1056/NEJMra1001389

Abstract

Triple-negative breast cancer, so called because it lacks expression of the estrogen receptor, progesterone receptor, and HER2, is often, but not always, a basal-like breast cancer. This review focuses on its origin, molecular and clinical characteristics, and treatment.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Breast Neoplasms* / drug therapy
Breast Neoplasms* / immunology
Breast Neoplasms* / mortality
Breast Neoplasms* / pathology
Female
Genes, BRCA1
Humans
Mutation
Prognosis
Receptor, ErbB-2
Receptors, Estrogen
Receptors, Progesterone
Survival Rate

Substances

Antineoplastic Agents
Receptors, Estrogen
Receptors, Progesterone
Receptor, ErbB-2